About AVT
Browse Articles
Customer Services

Short communication

Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy

Ruxandra Calin, Luc Paris, Anne Simon, Gilles Peytavin, Marc Wirden, Luminita Schneider, Marc-Antoine Valantin, Roland Tubiana, Rachid Agher, Christine Katlama

Corresponding author name: Christine Katlama
Corresponding author e-mail: christine.katlama@psl.aphp.fr

Citation: Antiviral Therapy 2012; 17:1601-1604
doi: 10.3851/IMP2344

Date accepted: 19 April 2012
Date published online: 03 September 2012


Background: The combination of raltegravir (RAL) and etravirine (ETR) represents a novel antiretroviral treatment option in patients with toxicity or long-term exposure to standard therapies including protease inhibitors (PI) and nucleoside reverse transcriptase inhibitors (NRTI). The objective of this study was to evaluate the capacity of dual RAL/ETR therapy to maintain virological suppression in HIV-1 patients under effective antiretroviral therapy (ART).

Methods: Using the Nadis database we retrospectively identified all patients in our centre who were switched from different ART regimens to ETR 200 mg twice daily plus RAL 400 mg twice daily prior to February 2010, having a suppressed HIV-1 plasma viral load (pVL<200 copies/ml) at the moment of switch. Patients already on RAL or ETR at baseline were not excluded from the study. Treatment failure was defined as two consecutive pVL>50 copies/ml or discontinuation of RAL/ETR for any reason.

Results: A total of 18 patients were included. Median baseline characteristics were: age 48 years (IQR 45–56), duration of ART 14 years (IQR 13–16), duration of viral suppression 6 years (IQR 5–9), duration of NRTI exposure 11 years (IQR 8–14) and PI exposure 6 years (IQR 3–9). In intent-to-treat analysis, the efficacy at 6 months of follow-up was 94.4% (n=17/18, 95% CI 74.2, 99%) and 83.3% (n=15/18, 95% CI 60.7, 94.1%) at 12 months. In per-protocol analysis, the efficacy at 12 months was 100% (n=15/15, 95% CI 80.6, 100%). No tolerability-related treatment discontinuation was recorded.

Conclusions: This study, although on a limited number of patients, suggests that raltegravir plus etravirine represents a potential option of NRTI/PI-sparing strategy, deserving further investigation in randomized studies.


Copyright © 2021 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.